Ga onbeperkt met Magzter GOLD

Ga onbeperkt met Magzter GOLD

Krijg onbeperkte toegang tot meer dan 9000 tijdschriften, kranten en Premium-verhalen voor slechts

$149.99
 
$74.99/Jaar

Poging GOUD - Vrij

Eyeing 20-20 Vision of Excellence

BioSpectrum Asia

|

BioSpectrum Asia Jan 2025

Dr Jogin Desai, Co-Founder & Chief Executive Officer, Eyestem Research

Eyeing 20-20 Vision of Excellence

A native of Ahmedabad and an expert in the field of drug development, Dr Jogin Desai incorporated his startup Eyestem Research in India, back in 2015, aiming to democratise access to cell therapy through a scalable cell therapy platform.

The journey of Eyestem started when Dr Desai met ophthalmologist Dr Rajani Battu (currently the Chief Medical Officer at Eyestem), in 2015, for a medical appointment that changed everything for both of them. Following the appointment, Dr Rajani introduced him to patients diagnosed with degenerative diseases of the eye and the terrible suffering they have to endure. He realised that dry age-related macular degeneration (AMD) is the largest cause of incurable blindness in the world for patients over 50 years. And this meant that for 196 million people suffering from this disease around the world, 40 million of which are in India, finding a cure is a need of the hour.

Eyestem, as a company, was initiated in late 2015 by Dr Jogin Desai, Dr Rajani Battu and Dr Dhruv Sareen, with a small project handed to a research team led by Dr Rajarshi Pal, then at Manipal Institute of Regenerative Medicine. A year later, Dr Desai approached Centre for Cellular and Molecular Platforms, C-CAMP, in Bengaluru, with the intention to incubate considering the state-of-the-art cell culture facilities and diverse funding and mentoring programmes available at C-CAMP. Dr Rajarshi Pal joined as a Co-Founder to incubate and lead the science.

MEER VERHALEN VAN BioSpectrum Asia

BioSpectrum Asia

BioSpectrum Asia

India signs MoU with Pfizer to strengthen healthcare innovation ecosystem

In a significant step towards strengthening India's healthcare innovation ecosystem, the Department for Promotion of Industry and Internal Trade (DPIIT), Ministry of Commerce and Industry, Government of India, has signed a Memorandum of Understanding (MoU) with US-based Pfizer Limited.

time to read

1 min

BioSpectrum Asia Oct 2025

BioSpectrum Asia

BioSpectrum Asia

New Zealand to lead new gene therapy trial for muscular dystrophy

The first clinical trial of a new treatment for a rare form of muscular dystrophy is being led by New Zealand-based University of Auckland's Centre for Brain Research.

time to read

1 min

BioSpectrum Asia Oct 2025

BioSpectrum Asia

BioSpectrum Asia

Scientists in Australia grow living skin in world-first

Australia's University of Queensland (UQ) researchers have been the first in the world to successfully grow fully functioning human skin in a laboratory.

time to read

1 min

BioSpectrum Asia Oct 2025

BioSpectrum Asia

BioSpectrum Asia

India joins Health AI Global Regulatory Network to strengthen oversight of AI in healthcare

HealthAI - The Global Agency for Responsible AI in Health, has welcomed India as a pioneer country joining the HealthAI Global Regulatory Network (GRN), a global network of health regulators dedicated to the safe and effective use of artificial intelligence (AI) in healthcare.

time to read

1 min

BioSpectrum Asia Oct 2025

BioSpectrum Asia

BioSpectrum Asia

TVM Capital Healthcare announces first closing of $150 M Southeast Asia Fund

Singapore-based TVM Capital Healthcare, a global private equity investor and operator specialised in healthcare growth capital across emerging markets, has announced the first closing of its $150 million TVM Healthcare Southeast Asia Fund (SEA Fund).

time to read

1 min

BioSpectrum Asia Oct 2025

BioSpectrum Asia

BioSpectrum Asia

National Yang Ming Chiao Tung University, TSH Biopharm collaborate to foster pharma talent in Taiwan

Taiwan's National Yang Ming Chiao Tung University (NYCU) and TSH Biopharm have signed a five-year industry-academia collaboration Memorandum of Understanding (MOU).

time to read

1 min

BioSpectrum Asia Oct 2025

BioSpectrum Asia

BioSpectrum Asia

Fujifilm Biosciences introduces BalanCD HEK293 Perfusion A Medium

Fujifilm Biosciences, a global leader in the innovation and manufacture of cell culture solutions for the life science market, has announced the commercial launch of BalanCD HEK293 Perfusion A.

time to read

1 min

BioSpectrum Asia Oct 2025

BioSpectrum Asia

BioSpectrum Asia

Korea makes smart patch that can run tests using sweat instead of blood

A research team at Korea Advanced Institute of Science and Technology has developed a smart patch that can precisely observe internal changes through sweat when simply attached to the body.

time to read

1 min

BioSpectrum Asia Oct 2025

BioSpectrum Asia

BioSpectrum Asia

ADB approves $106.9 M to strengthen secondary healthcare services in Sri Lanka

The Asian Development Bank (ADB) has approved a $106.9 million financing package to strengthen Sri Lanka's secondary curative care services, improve communicable disease prevention and control, and enhance the healthcare sector's governance and management capacity.

time to read

1 min

BioSpectrum Asia Oct 2025

BioSpectrum Asia

BioSpectrum Asia

Epigenic Therapeutics raises $60 M to accelerate clinical development of medicines

China-based startup Epigenic Therapeutics, a clinical-stage innovative drug development company, has announced the completion of a $60 million Series B round of financing led by Lapam Capital, with continued participation from existing investors Qiming Venture Partners and OrbiMed, and addition of new investors including IFSC and a renowned investment firm in the industry.

time to read

1 min

BioSpectrum Asia Oct 2025

Listen

Translate

Share

-
+

Change font size